Hutchin Hill Capital’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Hutchin Hill Capital’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10,300	Closed	-$122K	–	842
2017 Q3	$122K	Sell	10,300 -101,200	-91%	-$1.14M	﹤0.01%	710
2017 Q2	$1.17M	Buy	+111,500	New	+$1.14M	0.04%	465
2016 Q3	–	Sell	-103,400	Closed	-$1.13M	–	788
2016 Q2	$1.13M	Buy	+103,400	New	+$1.16M	0.04%	312
2016 Q1	–	Sell	-166,700	Closed	-$2.88M	–	866
2015 Q4	$2.88M	Sell	166,700 -21,800	-12%	-$391K	0.07%	246
2015 Q3	$3.75M	Buy	188,500 +123,100	+188%	+$2.82M	0.14%	193
2015 Q2	$1.07M	Buy	65,400 +22,500	+52%	+$390K	0.03%	447
2015 Q1	$668K	Buy	+42,900	New	+$665K	0.02%	508

Other funds holding SCMP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Hutchin Hill Capital's SCMP Position: Q4 2017 in Review

Hutchin Hill Capital sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2017, closing a stake of 10,300 shares — an estimated $122K sold.

Hutchin Hill Capital first reported a position in SCMP in Q1 2015 and held it in 7 quarters. The position peaked at $3.75M in Q3 2015. 188 funds tracked by Wall St. Rank hold SCMP as of Q4 2017.

Hutchin Hill Capital reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Hutchin Hill Capital sold 10,300 Sucampo Pharmaceuticals, Inc. shares in Q4 2017, an estimated $122K.
Hutchin Hill Capital first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2015 and held it in 7 quarters.
Hutchin Hill Capital's Sucampo Pharmaceuticals, Inc. position peaked at $3.75M in Q3 2015.
188 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2017.

Based on Hutchin Hill Capital's 13F filing for Q4 2017, filed 12 Feb 2018.